WALTHAM, Mass., March 22 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. announced today that the Corporate Compliance Staff of the NYSE Amex LLC (the "Exchange") has granted the Company an extension to meet the Exchange's continued listing standards and become compliant. The Company will remain listed up to June 23, 2010, subject to periodic review by the Exchange staff during the extension period of progress towards the Company's plan to regain compliance.
While the Company is taking steps to regain compliance with all applicable requirements for continued listing on the Exchange by June 23, 2010, there can be no assurance that the company will be able to do so in such time frame, or at all.
Interleukin Genetics, Inc. develops and markets genetic tests that empower consumers to prevent certain chronic diseases and that assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics markets a line of genetic tests under the Inherent Health((R)) brand including Bone Health, Weight Management, Heart Health and Nutritional Needs. The Company is headquartered in Waltham, MA. For more information please visit www.ilgenetics.com.
Interleukin Genetics, Inc.
